Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Fluoxetine

An SSRI antidepressant discovered in the United States in the early 1970s, first marketed in Belgium in 1986 and approved in the United States in 1987: it is used for depression, obsessive-compulsive disorder, bulimia and panic disorder. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The research started from a molecule similar to the antihistamine diphenhydramine: biochemist David T. Wong suggested testing its derivatives on serotonin reuptake, and fluoxetine proved the most selective.

FluoxetineGo to the active ingredient →
FluoxetineActive ingredientFluoxetineCat. No. P-F092-001CAS 54910-89-3

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.